87 related articles for article (PubMed ID: 21421033)
1. Molecular modeling of gel nanoparticles with cyclosporine A for oral drug delivery.
Tokarský J; Andrýsek T; Capková P
Int J Pharm; 2011 May; 410(1-2):196-205. PubMed ID: 21421033
[TBL] [Abstract][Full Text] [Related]
2. Novel gels and their dispersions--oral drug delivery systems for ciclosporin.
Murdan S; Andrýsek T; Son D
Int J Pharm; 2005 Aug; 300(1-2):113-24. PubMed ID: 16009515
[TBL] [Abstract][Full Text] [Related]
3. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation.
Yang SG
Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787
[TBL] [Abstract][Full Text] [Related]
4. Self-assembling colloidal system for the ocular administration of cyclosporine A.
Luschmann C; Tessmar J; Schoeberl S; Strauß O; Luschmann K; Goepferich A
Cornea; 2014 Jan; 33(1):77-81. PubMed ID: 24162754
[TBL] [Abstract][Full Text] [Related]
5. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results.
Gan L; Gan Y; Zhu C; Zhang X; Zhu J
Int J Pharm; 2009 Jan; 365(1-2):143-9. PubMed ID: 18773948
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and in silico modeling of biodegradable nanoparticles containing cyclosporine A and coenzyme Q10.
Ankola DD; Durbin EW; Buxton GA; Schäfer J; Bakowsky U; Kumar MN
Nanotechnology; 2010 Feb; 21(6):065104. PubMed ID: 20061595
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides.
Grove M; Müllertz A; Nielsen JL; Pedersen GP
Eur J Pharm Sci; 2006 Jun; 28(3):233-42. PubMed ID: 16650738
[TBL] [Abstract][Full Text] [Related]
8. Synchrotron radiation small- and wide- angle scattering study of dispergation of Equoral, a novel drug delivery system with cyclosporine A.
Uhríková D; Andrýsek T; Funari SS; Balgavý P
Pharmazie; 2004 Aug; 59(8):650-1. PubMed ID: 15378859
[TBL] [Abstract][Full Text] [Related]
9. Ophthalmic delivery of Cyclosporine A from Brij-97 microemulsion and surfactant-laden p-HEMA hydrogels.
Kapoor Y; Chauhan A
Int J Pharm; 2008 Sep; 361(1-2):222-9. PubMed ID: 18577433
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.
Guada M; Sebastián V; Irusta S; Feijoó E; Dios-Viéitez Mdel C; Blanco-Prieto MJ
Int J Nanomedicine; 2015; 10():6541-53. PubMed ID: 26527872
[TBL] [Abstract][Full Text] [Related]
11. Improvement of cyclosporine A bioavailability by incorporating ethyl docosahexaenoate in the microemulsion as an oil excipient.
Hirunpanich V; Sato H
Eur J Pharm Biopharm; 2009 Oct; 73(2):247-52. PubMed ID: 19560537
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration.
Borhade VB; Nair HA; Hegde DD
Drug Dev Ind Pharm; 2009 May; 35(5):619-30. PubMed ID: 18979309
[TBL] [Abstract][Full Text] [Related]
13. Drug and surfactant transport in Cyclosporine A and Brij 98 laden p-HEMA hydrogels.
Kapoor Y; Chauhan A
J Colloid Interface Sci; 2008 Jun; 322(2):624-33. PubMed ID: 18359493
[TBL] [Abstract][Full Text] [Related]
14. Topical administration of cyclosporin A in a solid lipid nanoparticle formulation.
Kim ST; Jang DJ; Kim JH; Park JY; Lim JS; Lee SY; Lee KM; Lim SJ; Kim CK
Pharmazie; 2009 Aug; 64(8):510-4. PubMed ID: 19746839
[TBL] [Abstract][Full Text] [Related]
15. Self-microemulsifying and microemulsion systems for transdermal delivery of indomethacin: effect of phase transition.
El Maghraby GM
Colloids Surf B Biointerfaces; 2010 Feb; 75(2):595-600. PubMed ID: 19892531
[TBL] [Abstract][Full Text] [Related]
16. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
17. The role of particle size distribution on bioavailability of cyclosporine: novel drug delivery system.
Andrýsek T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):3-8. PubMed ID: 12426766
[TBL] [Abstract][Full Text] [Related]
18. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems.
Sandri G; Bonferoni MC; Gökçe EH; Ferrari F; Rossi S; Patrini M; Caramella C
J Microencapsul; 2010; 27(8):735-46. PubMed ID: 21034366
[TBL] [Abstract][Full Text] [Related]
19. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri M; Mura P; Mora PC
Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
[TBL] [Abstract][Full Text] [Related]
20. Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function.
Zidan AS; Sammour OA; Hammad MA; Megrab NA; Habib MJ; Khan MA
Int J Pharm; 2007 Mar; 332(1-2):55-63. PubMed ID: 17169518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
